SOX: Re-empowering management

While the fine print has yet to be disclosed, Securities and Exchange Commission proposals to provide small company relief from the Sarbanes-Oxley Act look to be moving in the right direction, according to SEC watchers in the biotech industry.

At its meeting last week, SEC took steps toward permanent changes to ease the regulatory burden on smaller companies, previewing its long-awaited interpretive guidance and offering two amendments to existing rules.

It followed up later in the week by further extending the deadlines for small company compliance with the law's Section 404, which was designed to ensure internal control

Read the full 973 word article

How to gain access

Continue reading with a
two-week free trial.